SEATTLE, April 3, 2025 /PRNewswire/ -- In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results from the sentinel cohort of ...

The company aims to move cell therapies developed at Fred Hutchinson Cancer… Read More Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid ...

Spirulina under a microscope. Lumen Bioscience researchers engineered spirulina to biomanufacture a natural enzyme that they've shown destroys methanogens, the microbes in cows' rumen that ...

Seattle-based Lumen Bioscience has developed a new spirulina-based drug discovery, manufacturing and delivery platform for highly prevalent diseases that have been difficult to address with ...